TVTX Travere Therapeutics, Inc. Insider Trading

CLO Elizabeth E Reed sells 22,076 shares at blended avg $44.90 via pre-arranged 10b5-1 plan; stock near 52-week high of $44.91.

Elizabeth E Reed, Chief Legal Officer and General Counsel, executed two separate sales totaling 22,076 shares for $991,240.20 through a pre-arranged 10b5-1 trading plan adopted on 2025-06-16. The sales occurred at $45.00 and $43.95 per share with a blended average price of $44.90, near the 52-week high of $44.91 and just 0.3% below it. Following these sales, Reed's holdings decreased from 127,287 to 105,211 shares, a reduction of 17.3% of her pre-transaction position. Notably, Reed has executed 4 prior sales at TVTX in the days immediately preceding this filing (on 2026-04-14 and 2026-04-15), and the company is unprofitable with net income of $-37,102,000.00 for the latest quarter, though this transaction was scheduled rather than discretionary.

CMO Jula sold 20,311 shares for $913,668.45 via scheduled 10b5-1 plan; stock near 52-week peak

Jula filed 2 separate sales totaling 20,311 shares for $913,668.45, reducing her holdings by -15.2% from pre-transaction levels. The trades executed near the 52-week high, with the stock at -0.3% from the 52-week high of $44.91. This activity is part of a pre-arranged 10b5-1 trading plan adopted on 2025-05-28, making it scheduled rather than discretionary. While the stock has appreciated +47.0% over 30 days and +41.3% over 90 days, the company reported a net loss of $-37,102,000 and zero revenue in its latest quarter, indicating ongoing unprofitability that contrasts sharply with recent price strength.

CEO Eric Dube sold 22,500 shares for ~$989K near 52-week highs after heavy recent gains; prior exits have been poorly timed.

Eric Dube, Travere's CEO, sold shares near the stock's 52-week high following a substantial rally over the recent months. His track record on this specific stock is unfavorable: his two most recent sales in early April were executed before the stock rose significantly over the following quarter, leaving material gains unrealized. While the stock has recovered sharply from its lows and now trades near its peak, Dube's repeated pattern of selling before gains suggests weak judgment in timing exits—or, conversely, that he departed before the rally accelerated further. The company remains unprofitable with significant net losses, adding context to whether this sale reflects concern about valuation or simply portfolio management. This sale stands out primarily because a CEO selling near all-time highs and after the stock has already surged contradicts the classic insider-buying narrative; however, without clear evidence of deteriorating fundamentals or company guidance, the trade appears more ambiguous than alarming.

Director Roy D. Baynes sold 32,750 shares (46.6% of holdings) for $1,352,130 at $41.07–$42.12 on 2026-04-14.

Roy D. Baynes, a Director at Travere Therapeutics, executed 2 separate sales totaling 32,750 shares for $1,352,130, reducing his stake from 70,250 to 37,500 shares. The sales occurred at $41.07 and $42.12 per share, near the 52-week high of $42.13 and above the current price of $39.54. Across his prior open-market activity, Baynes's cross-ticker track record shows a 57.14% well-timed rate on 14 prior sells (with average 90-day returns of +5.4%), though this historical accuracy is not ticker-specific. The company's fundamentals show annual revenue growth of +110.4% and net income of $25.7M in the latest quarter, though full-year results remain negative; valuation stands at P/E 17.57 and market cap $3.6B.

CEO Eric M Dube sells 64,000 shares at $41.09 blended avg via scheduled 10b5-1 plan

On 2026-04-15, Dube executed 3 separate sales totaling 64,000 shares for $2,629,975.10 as part of a pre-arranged 10b5-1 trading plan adopted on 2025-06-16. His holdings reduced from 496,886 shares to 432,886 shares, a net reduction of 12.9% versus pre-transaction holdings. The scheduled nature of this transaction through a 10b5-1 plan means it was executed according to a pre-established formula, removing discretionary timing as an analytical variable. This type of programmatic selling is routine insider capital management and does not reflect real-time conviction signals about near-term stock performance.

CLO Reed sells 44,285 shares for $1.8M via pre-arranged 10b5-1 plan; holds 105.2K shares post-sale

Elizabeth Reed, Chief Legal Officer and General Counsel, executed 3 separate sales totaling 44,285 shares for $1,823,935.39 across two trading days (April 14-15, 2026) at prices ranging from $41.07 to $42.53. These dispositions were conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-06-16, meaning the sales were scheduled and not discretionary decisions made in response to current market conditions or company developments. The sale reduced her holdings from 149,496 shares to 105,211 shares, a decrease of 44,285 shares or 29.6% of her pre-transaction position. As a scheduled transaction executed through an established trading plan, this activity reflects previously committed positioning rather than a signal of near-term conviction or concern about TVTX valuation or trajectory.

CEO Eric M Dube sells 60,000 TVTX shares for $1.9M; stock down 23.0% in 90 days; recent prior sales also in negative territory

Eric M Dube, Chief Executive Officer of Travere Therapeutics, executed 2 separate sales totaling 60,000 shares (60.0K shares) for $1,855,839.18 at an average price of $30.93 on 2026-04-01, reducing his holdings from 492,886 shares to 432,886 shares (a 12.2% reduction). The stock has declined 23.0% over the 90 days prior to this sale and is currently trading at $30.44, down 24.4% from its 52-week high of $40.28. Notably, Dube's prior five trades at TVTX have shown a consistent pattern of negative short-term outcomes: his four most recent sales (2026-01-23 through 2026-02-20) all posted 30-day declines ranging from 1.2% to 16.5%, with none yet measurable at the 90-day horizon. While company fundamentals remain solid—revenue of $164,859,000.00 with annual growth of 110.4%, net income of $25,706,000.00, and a P/E of 13.53—the cumulative pattern of insider sales during a sustained equity decline warrants attention to whether factors driving the stock's descent may be material to ongoing operations.

TVTX CEO Eric M Dube sold 60,000 shares at $30.10 via 10b5-1 plan; retains 432,886 shares

CEO Eric M Dube sold 60,000 shares of Travere Therapeutics at $30.10 on 2026-02-20 for $1,805,766.00 under a 10b5-1 trading plan adopted on 2025-06-16. This is a scheduled, pre-arranged transaction rather than a discretionary trade, eliminating timing-based interpretation. The sale reduces his holdings by 12.2%, from 492,886 shares to 432,886 shares post-transaction. Investors should note this represents a material reduction in CEO equity exposure, though the plan's mechanical nature—established months in advance—prevents attribution to current market conditions or company outlook.

TVTX CEO Dube sells 100,087 shares in 2 transactions ($3.2M) under pre-arranged 10b5-1 plan

Chief Executive Officer Eric M Dube executed 2 separate sales totaling 100,087 shares for $3,230,315.62 on 2026-02-03, reducing his holdings from 532,973 shares to 432,886 shares. This sale is part of a pre-arranged 10b5-1 trading plan adopted on 2025-06-16, meaning the transaction was scheduled in advance rather than discretionary. The -18.8% reduction in his stake represents a substantial share disposition, though the scheduled nature of the transaction limits inference of timing intent or market sentiment.

CEO Eric M Dube sold 60,000 shares (60.0K shares) for $1,805,134.22 under pre-arranged 10b5-1 plan

Eric M Dube, Chief Executive Officer, executed two separate sales totaling 60,000 shares for $1,805,134.22 on 2026-01-23 and 2026-01-27 at blended average price $30.09. This transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-06-16, making it scheduled rather than discretionary. Post-transaction holdings of 419,173 shares represent a 12.5% reduction from pre-transaction levels of 479,173 shares. As a scheduled plan transaction, this sale conveys no information about timing judgment or conviction changes; it reflects pre-established execution at dates and quantities determined months in advance.